Sarepta Therapeutics, Inc. (SRPT) stock
SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/3085% below fair value
$16.07+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $1.70BP/E –Yield –
Sarepta Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Sarepta Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -2.5%. For fiscal 2025 it was -31.8%, against 11.5% the year before. The highest annual figure on record is 11.5% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -31.8% | −43.3 |
| FY2024 | Dec 31, 2024 | 11.5% | +33.0 |
| FY2023 | Dec 31, 2023 | -21.5% | +35.9 |
| FY2022 | Dec 31, 2022 | -57.5% | +8.0 |
| FY2021 | Dec 31, 2021 | -65.5% | +39.0 |
| FY2020 | Dec 31, 2020 | -104.5% | +80.8 |
| FY2019 | Dec 31, 2019 | -185.3% | −71.1 |
| FY2018 | Dec 31, 2018 | -114.1% | −3.1 |
| FY2017 | Dec 31, 2017 | -111.0% | +4809.3 |
| FY2016 | Dec 31, 2016 | -4920.3% | +12652.2 |
| FY2015 | Dec 31, 2015 | -17572.5% | −16201.3 |
| FY2014 | Dec 31, 2014 | -1371.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -2.4% | +23.5 |
| Q2 FY2026 | Jun 30, 2026 | 3.3% | −15.6 |
| Q1 FY2026 | Mar 31, 2026 | 49.0% | +89.4 |
| Q4 FY2025 | Dec 31, 2025 | -92.9% | −117.5 |
| Q3 FY2025 | Sep 30, 2025 | -25.9% | −30.6 |
| Q2 FY2025 | Jun 30, 2025 | 18.9% | +19.1 |
| Q1 FY2025 | Mar 31, 2025 | -40.3% | −48.8 |
| Q4 FY2024 | Dec 31, 2024 | 24.6% | +18.4 |
| Q3 FY2024 | Sep 30, 2024 | 4.8% | +11.0 |
| Q2 FY2024 | Jun 30, 2024 | -0.2% | +50.9 |
| Q1 FY2024 | Mar 31, 2024 | 8.4% | +62.9 |
| Q4 FY2023 | Dec 31, 2023 | 6.2% | +47.5 |
| Q3 FY2023 | Sep 30, 2023 | -6.3% | +50.8 |
| Q2 FY2023 | Jun 30, 2023 | -51.1% | +39.3 |
| Q1 FY2023 | Mar 31, 2023 | -54.5% | −13.3 |
| Q4 FY2022 | Dec 31, 2022 | -41.3% | +11.2 |
| Q3 FY2022 | Sep 30, 2022 | -57.0% | −38.9 |
| Q2 FY2022 | Jun 30, 2022 | -90.4% | +11.7 |
| Q1 FY2022 | Mar 31, 2022 | -41.2% | +62.1 |
| Q4 FY2021 | Dec 31, 2021 | -52.5% | +65.1 |
| Q3 FY2021 | Sep 30, 2021 | -18.2% | +77.0 |
| Q2 FY2021 | Jun 30, 2021 | -102.1% | −1.4 |
| Q1 FY2021 | Mar 31, 2021 | -103.4% | +0.5 |
| Q4 FY2020 | Dec 31, 2020 | -117.6% | +112.3 |
| Q3 FY2020 | Sep 30, 2020 | -95.2% | +29.6 |
| Q2 FY2020 | Jun 30, 2020 | -100.7% | +190.2 |
| Q1 FY2020 | Mar 31, 2020 | -103.8% | −16.0 |
| Q4 FY2019 | Dec 31, 2019 | -230.0% | −64.9 |
| Q3 FY2019 | Sep 30, 2019 | -124.8% | −35.5 |
| Q2 FY2019 | Jun 30, 2019 | -290.9% | −150.2 |
| Q1 FY2019 | Mar 31, 2019 | -87.8% | −40.2 |
| Q4 FY2018 | Dec 31, 2018 | -165.1% | −124.7 |
| Q3 FY2018 | Sep 30, 2018 | -89.3% | +10.6 |
| Q2 FY2018 | Jun 30, 2018 | -140.7% | +40.3 |
| Q1 FY2018 | Mar 31, 2018 | -47.6% | +192.6 |
| Q4 FY2017 | Dec 31, 2017 | -40.4% | +1590.2 |
| Q3 FY2017 | Sep 30, 2017 | -99.9% | – |
| Q2 FY2017 | Jun 30, 2017 | -180.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -240.1% | – |
| Q4 FY2016 | Dec 31, 2016 | -1630.6% | – |
See a number that looks wrong?